Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Recovery of Breakthrough Asthma Attacks Treated With Oral Steroids While on Monoclonal Antibody Therapy: Protocol for a Prospective Observational Study (BOOST)

Howell I. et al, (2023), JMIR Research Protocols, 12, e46741 - e46741

An ACAT inhibitor suppresses SARS-CoV-2 replication and boosts antiviral T cell activity.

Wing PAC. et al, (2023), PLoS pathogens, 19

Epithelial immune activation and intracellular invasion by non-typeable Haemophilus influenzae

Brown MA. et al, (2023), Frontiers in Cellular and Infection Microbiology, 13

Editorial: MAIT cells come of age

Corbett AJ. et al, (2023), Frontiers in Immunology, 14

MAIT cells and the microbiome.

Jabeen MF. and Hinks TSC., (2023), Frontiers in immunology, 14

BIO-AST Biologics for chronic severe asthma: a network meta-analysis

Crossingham I. et al, (2022), Cochrane Database of Systematic Reviews, 2022

Sub‐stratification of type‐2 high airway disease for therapeutic decision‐making: A ‘bomb’ (blood eosinophils) meets ‘magnet’ ( FeNO ) framework

Couillard S. et al, (2022), Respirology, 27, 573 - 577

Longitudinal changes in sputum and blood inflammatory mediators during FeNO suppression testing.

Couillard S. et al, (2022), Thorax

Identifying Bacterial Airways Infection in Stable Severe Asthma Using Oxford Nanopore Sequencing Technologies

Jabeen MF. et al, (2022), Microbiology Spectrum, 10

The bacteriology of pleural infection (TORPIDS): an exploratory metagenomics analysis through next generation sequencing

Kanellakis NI. et al, (2022), The Lancet Microbe, 3, e294 - e302

Predicting the benefits of type-2 targeted anti-inflammatory treatment with the prototype OxfoRd Asthma attaCk risk scaLE (ORACLE)

Couillard S. et al, (2022), ERJ Open Research, 00570 - 2021

Azithromycin for mild-to-moderate COVID-19 - Authors' reply.

Hinks TSC. and ATOMIC2 trial authors None., (2021), The Lancet. Respiratory medicine, 9, e100 - e101

The circadian clock component BMAL1 regulates SARS-CoV-2 entry and replication in lung epithelial cells

Zhuang X. et al, (2021), iScience, 24, 103144 - 103144

Subcutaneous omalizumab for people with asthma

Donovan T. et al, (2021), Cochrane Database of Systematic Reviews, 2021

Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial.

Hinks TSC. et al, (2021), The Lancet. Respiratory medicine

The circadian clock component BMAL1 regulates SARS-CoV-2 entry and replication in lung epithelial cells.

Zhuang X. et al, (2021), bioRxiv

Combination fixed-dose beta agonist and steroid inhaler as required for adults or children with mild asthma

Crossingham I. et al, (2021), Cochrane Database of Systematic Reviews

A randomised clinical trial of azithromycin versus standard care in ambulatory COVID-19 – the ATOMIC2 trial

Hinks TSC. et al, (2021)

A Randomised Clinical Trial of Azithromycin Versus Standard Care in Ambulatory COVID-19 – The ATOMIC2 Trial

Hinks TSC. et al, (2021), SSRN Electronic Journal

Hypoxic and pharmacological activation of HIF inhibits SARS-CoV-2 infection of lung epithelial cells

Wing PAC. et al, (2021), Cell Reports, 35, 109020 - 109020

Load More

Include forthcoming?